DNA甲基化检测技术市场－全球产业规模、份额、趋势、机会及预测（按技术、应用、产品、最终用户、地区和竞争格局划分，2021-2031年）

全球DNA甲基化检测技术市场预计将从2025年的42.2亿美元成长到2031年的84.1亿美元，复合年增长率达到12.18%。

这项技术涵盖了用于识别和测量表观遗传修饰的分析方法，特别是DNA分子上甲基化的修饰，这种修饰能够在不改变碱基序列的情况下调控基因表现。该市场成长的主要驱动力是肿瘤和慢性疾病在全球范围内日益增长的影响，从而产生了对可靠生物标记的迫切需求，以支持早期检测和精准医疗。根据美国癌症协会预测，2024年美国预计将新增约2,001,140例癌症病例，凸显了此类诊断能力的重要性。

非侵入性液态生物检体技术的日益普及进一步推动了这一领域的发展。该技术利用甲基化模式以极高的灵敏度检测循环肿瘤DNA，使临床医生能够比传统组织切片检查更有效地制定个人化治疗方案。然而，市场面临一个重大障碍：高通量定序设备成本高昂，这可能会限制其广泛应用并阻碍市场整体扩张。

市场驱动因素

液态生物检体在非侵入性诊断领域，尤其是在癌症早期检测和监测方面的日益普及，正成为推动市场成长的主要动力。这些检测利用甲基化模式高特异性地识别循环肿瘤DNA，为患者提供了比侵入性组织取样更便捷的选择。主要企业正经历这些基于甲基化的筛检工具的显着商业性应用，不仅提升了其临床效用，也推动了市场渗透。例如，Exact Sciences在其2024年2月发布的「2023年第四季度收益报告」中指出，筛检业务（包括基于甲基化的Cologuard检测）在2023年全年的收入达到18.6亿美元，这表明表观遗传生物标誌物在常规筛检和预防性医疗保健模式中的重要性日益凸显。

同时，政府和私人机构对表观基因学研究投入的增加正在加速创新并提高其可及性。联邦预算优先考虑依赖先进基因组分析来降低死亡率的肿瘤学倡议，从而创造有利于产品快速开发的环境。 2024年4月，美国癌症研究协会（AACR）报告称，美国国家癌症研究所（NCI）已获得72亿美元的2024财年拨款，用于支持关键研究计画。这笔资金将用于开发利用次世代定序平台和DNA甲基化技术的精准肿瘤学工具。作为这一整体市场成长动能的例证，Guardant Health公司报告称，其2024年第三季营收达1.915亿美元，年增34%。

市场挑战

高通量定序设备所需的巨额资本和营运成本是全球DNA甲基化检测技术市场扩张的主要障碍。这些先进的平台对于以所需灵敏度识别甲基化模式至关重要，但其高昂的实施成本给小规模临床检查室和研究机构的预算带来了沉重负担。这种经济负担不仅限于初始购买成本，还包括昂贵的试剂、专业的生物资讯基础设施以及解读复杂表观遗传数据的高技能人员。因此，这种高成本结构限制了该技术在价格敏感地区和社区医院的应用，使其主要局限于资金雄厚的学术机构和参考实验室。

这些财务障碍迫使实验室缩减或取消诊断服务，从而抑制了市场成长。据美国诊断和实验室医学学会 (ADLM) 称，到 2024 年，约 48% 的受访临床检查室预计将被迫停止某些检查室自主开发的检测服务，原因是维持合规性和检验复杂诊断流程所带来的过重财务和资源负担。这一趋势凸显了购置和维护先进基因组学设备成本的不断攀升如何有效地减少了市场参与企业的数量，并阻碍了基于甲基化的诊断技术的广泛应用。

市场趋势

第三代定序的引进正在革新市场，它无需进行有害的亚硫酸氢盐转化即可直接检测甲基化。与传统的化学修饰DNA并降低样本品质的方法不同，奈米孔定序能够读取表观遗传修饰的天然状态，并在长读长资料中区分5-甲基胞嘧啶和5-羟甲基胞嘧啶。这项技术变革显着提高了数据准确性，简化了高通量实验室的工作流程，并加速了天然定序平台相对于复杂化学转换通讯协定的普及。牛津奈米孔技术公司（Oxford Nanopore Technologies plc）于2025年3月发布的「截至2024年12月31日的年度表现」凸显了市场对这种先进直接定序技术的需求。业绩显示，其支持高功率天然甲基化分析的PromethION产品线营收成长55.8%，达到7,590万英镑。

同时，人工智慧 (AI) 与机器学习的融合正成为解决海量表观遗传资料集分析复杂性的关键趋势。由于甲基化谱分析会产生高维度数据，人工智慧演算法正被用于识别新的生物标记并预测患者预后，其准确性已超越人工生物资讯流程。临床医疗机构正迅速将这项计算技术的进步转化为商业价值，他们希望透过整合基因组学和临床模式的智慧诊断来实现精准医疗。为了反映人工智慧驱动的基因组学领域的成长，Tempus AI 在 2025 年 2 月发布的「2024 年第四季及全年财务表现」报告中指出，其基因组学部门（该部门利用人工智慧驱动的精准医疗模型）2024 年全年的收入达到 4.517 亿美元。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球DNA甲基化检测技术市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过技术（聚合酵素链锁反应（PCR）、微阵列、定序、其他技术）
  • 按应用领域（转化研究、诊断程序）
  • 依产品分类（耗材、设备、软体）
  • 按最终用户划分（合约研究组织 (CRO)、研究/学术机构、生物製药/生物技术公司、其他最终用户）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美DNA甲基化检测技术市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲DNA甲基化检测技术市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区DNA甲基化检测技术市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲DNA甲基化检测技术市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美DNA甲基化检测技术市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球DNA甲基化检测技术市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Agilent Technologies, Inc.
• Abcam Limited
• Bio-Rad Laboratories, Inc
• Illumina, Inc
• Qiagen NV
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Pacific Biosciences of California, Inc.
• Merck KGaA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global DNA Methylation Detection Technology Market is projected to expand from USD 4.22 Billion in 2025 to USD 8.41 Billion by 2031, achieving a compound annual growth rate (CAGR) of 12.18%. This technology involves analytical methods designed to identify and measure epigenetic modifications, specifically where methyl groups attach to DNA molecules to regulate gene expression without changing the underlying sequence. The market is largely propelled by the rising global impact of oncology and chronic diseases, which generates an urgent demand for robust biomarkers to support early detection and precision medicine. According to the American Cancer Society, approximately 2,001,140 new cancer cases are expected in the United States in 2024, underscoring the critical need for these diagnostic capabilities.

This sector is further bolstered by the growing utilization of noninvasive liquid biopsy applications, which leverage methylation patterns to detect circulating tumor DNA with exceptional sensitivity. These technological advancements enable clinicians to customize therapeutic strategies more effectively than traditional tissue biopsies allow. However, the market encounters a major obstacle due to the significant costs involved with high-throughput sequencing instruments, which may restrict broad implementation and hinder overall market expansion.

Market Driver

The rising adoption of liquid biopsy for non-invasive diagnostics serves as a major catalyst for growth, particularly regarding early cancer detection and monitoring. These tests employ methylation patterns to identify circulating tumor DNA with high specificity, providing a patient-friendly alternative to invasive tissue sampling. Leading diagnostic companies are experiencing significant commercial uptake of these methylation-based screening tools, confirming their clinical utility and driving market penetration. For example, Exact Sciences noted in their 'Fourth Quarter 2023 Earnings Report' in February 2024 that screening revenue, including the methylation-based Cologuard test, hit $1.86 billion for the full year 2023, reflecting a growing dependence on epigenetic biomarkers for routine screening and preventative healthcare models.

Concurrently, the expansion of government and private funding for epigenomics research is accelerating technological innovation and accessibility. Federal budgets are increasingly prioritizing oncology initiatives that rely on advanced genomic analysis to lower mortality rates, fostering an environment conducive to rapid product development. The American Association for Cancer Research reported in April 2024 that the National Cancer Institute (NCI) received a $7.2 billion appropriation for fiscal year 2024 to support critical research programs. This financial influx supports the development of next-generation sequencing platforms and precision oncology tools utilizing DNA methylation. Illustrating this broader market momentum, Guardant Health reported a 34% revenue increase to $191.5 million in the third quarter of 2024 compared to the previous year.

Market Challenge

The substantial capital and operational expenditures required for high-throughput sequencing instruments constitute a primary barrier to the expansion of the Global DNA Methylation Detection Technology Market. These sophisticated platforms, which are essential for identifying methylation patterns with the necessary sensitivity, command high acquisition prices that strain the budgets of smaller clinical laboratories and research institutions. The financial burden extends beyond the initial purchase to include costly reagents, specialized bioinformatics infrastructure, and the need for highly skilled personnel to interpret complex epigenetic data. Consequently, this high cost structure limits the technology's penetration in price-sensitive regions and community hospital settings, restricting its availability largely to well-funded academic centers and reference laboratories.

This financial impediment directly forces testing facilities to scale back or abandon their diagnostic offerings, thereby stalling market growth. According to the Association for Diagnostics & Laboratory Medicine, in 2024, approximately 48% of surveyed clinical laboratories indicated they would be compelled to discontinue specific laboratory-developed testing services due to the prohibitive financial and resource demands associated with maintaining compliance and validation for such complex diagnostic workflows. This trend highlights how escalating costs associated with deploying and maintaining advanced genomic instrumentation effectively reduce the number of active market participants, thereby hampering the widespread adoption of methylation-based diagnostics.

Market Trends

The implementation of third-generation sequencing is revolutionizing the market by enabling direct methylation detection without the need for damaging bisulfite conversion. Unlike traditional methods that chemically alter DNA and degrade sample quality, nanopore sequencing allows for the native reading of epigenetic modifications, distinguishing between 5-methylcytosine and 5-hydroxymethylcytosine on long reads. This technological shift significantly enhances data accuracy and simplifies workflows for high-throughput laboratories, driving the adoption of native sequencing platforms over complex chemical conversion protocols. Validating this demand for advanced direct sequencing capabilities, according to Oxford Nanopore Technologies plc, March 2025, in the 'Annual results for the year ended 31 December 2024', revenue from the PromethION product range, which supports high-output native methylation profiling, grew 55.8% to £75.9 million.

Simultaneously, the integration of artificial intelligence and machine learning is emerging as a critical trend to address the complexity of analyzing massive epigenetic datasets. As methylation profiling generates high-dimensional data, AI algorithms are increasingly deployed to identify novel biomarkers and predict patient outcomes with greater precision than manual bioinformatics pipelines can achieve. This computational advancement is rapidly monetizing as clinical providers seek intelligent diagnostics that combine genomic and clinical modalities to tailor precision medicine. Reflecting this growth in AI-driven genomic utility, according to Tempus AI, February 2025, in the 'Fourth Quarter and Full Year 2024 Results', the company reported that its Genomics segment revenue, which leverages AI-driven precision medicine models, reached $451.7 million for the full year 2024.

Key Market Players

• Agilent Technologies, Inc.
• Abcam Limited
• Bio-Rad Laboratories, Inc
• Illumina, Inc
• Qiagen N.V.
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Pacific Biosciences of California, Inc.
• Merck KGaA

Report Scope

In this report, the Global DNA Methylation Detection Technology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Methylation Detection Technology Market, By Technology

• Polymerase Chain Reaction (PCR)
• Microarray
• Sequencing
• Other Technologies

DNA Methylation Detection Technology Market, By Application

• Translational Research
• Diagnostic Procedure

DNA Methylation Detection Technology Market, By Product

• Consumables
• Instruments
• Software

DNA Methylation Detection Technology Market, By End User

• Contract Research Organization (CRO)
• Research and Academic Laboratories
• Biopharmaceutical and Biotech Companies
• Other End User

DNA Methylation Detection Technology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Methylation Detection Technology Market.

Available Customizations:

Global DNA Methylation Detection Technology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global DNA Methylation Detection Technology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Polymerase Chain Reaction (PCR), Microarray, Sequencing, Other Technologies)
  • 5.2.2. By Application (Translational Research, Diagnostic Procedure)
  • 5.2.3. By Product (Consumables, Instruments, Software)
  • 5.2.4. By End User (Contract Research Organization (CRO), Research and Academic Laboratories, Biopharmaceutical and Biotech Companies, Other End User)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America DNA Methylation Detection Technology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Product
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States DNA Methylation Detection Technology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada DNA Methylation Detection Technology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico DNA Methylation Detection Technology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By End User

7. Europe DNA Methylation Detection Technology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Product
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany DNA Methylation Detection Technology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By End User
  • 7.3.2. France DNA Methylation Detection Technology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom DNA Methylation Detection Technology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy DNA Methylation Detection Technology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain DNA Methylation Detection Technology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By End User

8. Asia Pacific DNA Methylation Detection Technology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Product
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China DNA Methylation Detection Technology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By End User
  • 8.3.2. India DNA Methylation Detection Technology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan DNA Methylation Detection Technology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea DNA Methylation Detection Technology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia DNA Methylation Detection Technology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By End User

9. Middle East & Africa DNA Methylation Detection Technology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Product
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia DNA Methylation Detection Technology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE DNA Methylation Detection Technology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa DNA Methylation Detection Technology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By End User

10. South America DNA Methylation Detection Technology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Product
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil DNA Methylation Detection Technology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia DNA Methylation Detection Technology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina DNA Methylation Detection Technology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global DNA Methylation Detection Technology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abcam Limited
• 15.3. Bio-Rad Laboratories, Inc
• 15.4. Illumina, Inc
• 15.5. Qiagen N.V.
• 15.6. Thermo Fisher Scientific, Inc.
• 15.7. F. Hoffmann-La Roche Ltd.
• 15.8. Hologic, Inc.
• 15.9. Pacific Biosciences of California, Inc.
• 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer